Skip to main content
ACET
NASDAQ Life Sciences

Adicet's Prula-cel Shows 50% Complete Renal Response in Lupus Nephritis, Pivotal Study Planned

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$9.99
Mkt Cap
$84.441M
52W Low
$6.01
52W High
$17.438
52W Position info
66% above low
Off High info
43% below high
Rel. Volume info
5.4× avg
Market data snapshot near publication time

ACET sits 66% above its 52-week low of $6.01 on elevated volume (5.4× avg).

Summary

Adicet Bio reported positive Phase 1 data for prula-cel in systemic lupus erythematosus (SLE) with or without lupus nephritis (LN). At 12 months, 50% of evaluable LN patients achieved complete renal response and 54% achieved DORIS remission, with responses ongoing up to 21 months. Safety was favorable: no CRS above Grade 2, no ICANS, no IEC-HS, supporting outpatient dosing. The company has aligned with the FDA on a single-arm pivotal study in LN and plans to initiate start-up activities in Q4 2026, with potential expansion to non-renal SLE. This is the first disclosure of these efficacy results and the pivotal study design, following the 8-K on September 1 that announced completion of the last patient visit and expected topline data in September. The data de-risks the program and sets a clear regulatory path, a major catalyst for a company with a market cap around $84 million.

Updates

  1. · SEC 8-K — The 8-K includes the full press release and corporate presentation, and notes the company will host a webcast at 8:00 a.m. ET today.

At the time of this announcement, ACET was trading at $9.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.4M. The 52-week trading range was $6.01 to $17.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

ACET - Latest Insights

ACET
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.95
Real-time Price: $2.20 info
Change: -$0.7482 (-25%) info
Market Cap: $20.034M info
ACET
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.95
Real-time Price: $2.20 info
Change: -$0.7482 (-25%) info
Market Cap: $20.034M info
ACET
Sep 28, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $8.96
Real-time Price: $2.20 info
Change: -$6.76 (-75%) info
Market Cap: $20.034M info
ACET
Sep 01, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.72
Real-time Price: $2.20 info
Change: -$6.52 (-75%) info
Market Cap: $20.034M info
ACET
Aug 27, 2026, 4:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.97
Real-time Price: $2.20 info
Change: -$6.77 (-75%) info
Market Cap: $20.034M info